Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease

Main Article Content

Yukiko Miura
Takefumi Saito
Kazutaka Fujita
Toru Tanaka
Yoshiya Tsunoda
Arata Azuma
Takahito Nei
Yohei Yatagai
Shigen Rin
Akimasa Sekine
Kenji Hayashihara


Antifibrotic agent, interstitial lung disease, pirfenidone, scleroderma, vital capacity


Interstitial lung disease is the most common complication and cause of death among patients with scleroderma. Scleroderma-related interstitial lung disease has usually been treated with cyclophosphamide; however, its effect was evaluated to be modest and long-term administration of this drug is associated with adverse effects. Herein, we report our clinical experience of administering pirfenidone, which is an antifibrotic agent, in five patients with scleroderma-related interstitial lung disease. All patients demonstrated an increase in vital capacity.
Abstract 178 | PDF Downloads 179